Multivitamin Study Results, Vivus Craters On Q3: Healthcare Business Wrap

A study over 11 years indicates that taking multivitamins daily failed to reduce the risk of a heart attack or stroke in a sample group of more than 14,500 men over the age of 50, but there did seem to be a reduced risk of cancer. Firms operating in the sector include Pfizer, which provided the vitamins for the study, along with NBTY and Schiff Nutrition International (NYSE:SHF).

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Shares of Vivus (NASDAQ:VVUS) lost more than 20 percent on the day after a disappointing third quarter report earlier on Tuesday. Even though revenue improved bottom line results missed estimates because of higher Qsymia-related costs. Moreover, the firm indicated in its conference call that the lack of insurer coverage is a “big concern,” and is impacting sales of the weight-loss drug.

Lexicon Pharmaceuticals (NASDAQ:LXRX) finished down 4 percent on the day, in the face of its earlier announcement that favorable data from Phase 2b clinical trials of its diabetes drug LX4211 was then being presented at the American Heart Association Scientific Sessions Conference in Los Angeles.

Don’t Miss: Multivitamin Study Could Be Bad News for These Stocks.